The compassionate use program is for patients with pediatric diffuse midline glioma (DMG) and DIPG. OKN-007 is an experimental drug that works on the tumor microenvironment. See https://oblatoinc.com/our-science/#01 for details.
There are also clinical trials going on for this drug for both newly diagnosed and recurrent Glioblastoma. I am excited about this drug - as we (the Musella Foundation) gave them one of their first brain tumor research grants to get this drug started 9 years ago and have been keeping up with their research since then.
xCures is running the expanded access program for Oblato. (Disclaimer: I am a paid consultant to xCures). This program is being run the way all expanded access programs should be run - and the way we ran the original Onc-201 trial- collect the data from the patients the same as if in a regular trial so we can learn from every patient's experiences. This data can be used to confirm the data from the trials and hopefully speed up FDA and insurance approvals.